would not be surprised if an upgrade came in the 16-20 range. The only issue is how do 48 m shares cover with no float?
BUT we all knew that. Prolar drug getting monetized near cost of that deal. Might even make that deal profitable.
nice position to be in. Cash will be over 500m upon approval.
Amazing, simply hilarious, rolling on the floor, worthless, good one bozzo. 1/2 A BILLION for HALF the profits, omfg, BOZZO you nailed that one.
What was PFE thinking? Did they not read that LW said the drug was WORTHLESS and they are giving OPK A half billion up FRONT WOW.
Figure we exit 2016 Jan 2017 about 200% higher. Closer to 30 than 7.
Home tree, let us think about the humor of home tree. Well, 295 million upfront when Boza said Prolar was not worth more than 100k, ouch, and that 295 is only the down payment on one drug. Talk about SMOKE by a Jamoke, blowing smoke, with no idea what he was toking about.
week, news keeps getting better and better. How do you cover 48 m shares again with NO float, oh yah, at higher prices. Heading on up, upgrade from a GS, Mer, etc to mid teens could do it. It is coming.
Enough cash to last a decade at current burn rate, 809 million cash is HUGE.
this cash right bio.
market up .07%, I see a pattern here. Look forward to more ROBO rapid fire posts, they post fast, opko goes up. I guess if they DID not post Opko would go down, must be how it works. So keep up the good work, I do not mind not reading pages upon pages of blather. Yes, and this post is a great example of they type I TOO would ignore, but JUST having fun.
there is such confusion here.
" By the way, I'm pleased to confirm that our preparation of the NDA is well-advanced. Our targeted submission date is prior to year end, which will put the NDA in a position to be filed by the FDA in the first quarter of 2015. "
So WHO FILES the NDA? READ carefully. THE FDA. Who submits? Opk. The company originally said in this quote they would submit by EOY. They later stated shortly after EOY for submission at JP Morgan. So submitting is done and we are waiting on the FDA to file.
The time frame from submission by company, and NDA filing by the FDA is 60 days. So if they submitted Dec 31, the latest date should be roughly FEB 28. If they submitted Jan 15, NDA March 15th. Opko technically only submits an application, the FDA has 60 days to notify OPKO that the NDA is FILED and accepted for review.
Dr James Mohler stated that the 4kscore " “Test will find the proper space early on in disease and I look forward to that happening”.
This is From Uncle's site. MY take: The new guidelines will be out shortly, expect 4k to be FRONT and CENTER in those guidelines. Figure Mohler chairs the committee, he likes the test, he has clout. Also there are Memorial Sloan people on this committee, they invented 4kscore. I now believe it is a done deal.
No way of knowing WHY Schwab is recalling shares, I can not verify they are, I do not have a Schwab account, but with 113 million shares in retail hands, removing yours is important. Who is to say a LONG did not just recall 2-3 million from the Schwab program, triggering the recall? Fully 1/2 of the shorted shares are from retail LONGS who are net short picking up a % for the loan. Shooting ones own foot, never prudent.
raised pt to 9.00, A week ago Cantor Fitzgerald reiterated buy calling arry their number one small cap pick but only had a 7.00 pt, so Cantor, raise your target back to 9.00. With a cash infusion equal to 22% of the market cap, plus the return of a drug still not sure why the targets are not in the 11-12 range.
highest level since LAST April, short interest grew 9m since then, so those that have not covered might shortly, as most profits went puff.
2015 and 2016. The info I used was from yahoo estimates. ALL FIRMS, well, both of those who gave estimates have yanked those estimates. As mentioned yesterday they did not include the two near 400m cash injections. My thought is as soon as they figure out which " LINES " this money hits, and if it does hit eps., not just cash on hand, we get a 14-15 price target. Might take two weeks, but we will get an upgrade, INMHO, eps. line projections could go from neg to positive, GS a recent buyer will take note.
OK, GS read this, give opk an upgrade, thanks. We have no impact, but I am trying, lol.
Oppenheimer’s Vanjani says five key factors underlie his investment thesis for OPKO: the company’s 4Kscore algorithm for prostate cancer detection is expected to become a standard care test in risk stratifying patients for biopsy; the test will move outside of the one million biopsy procedure market and begin to take a share from total and free PSA testing; adoption of the Claros 1 point-of-care test will proceed, with significant value obtained in the vitamin D testing arena; in conjunction with increased point-of-care vitamin D testing by Claros 1, Rayaldee will penetrate and take share in the prescription vitamin D market; and the hGH-CTP profile of once-weekly dosing will resonate with physicians and patients, and the product will take share in the human growth hormone market.
Wonder if this is part of the reason for the little pop today. Frost has announced things at these conferences in the past, so a few shorts might be stepping aside just in case. I am hoping there is word on the Rayaldee filing, any other news will be a bonus.
The two biggest pieces of the short thesis put out there by some unnamed hedge fund is that the pipeline has no to little value, and that Opko grossly OVERPAID for Prolar and used stock to do it. Strange how they call Opko out for using stock, when it is used by most companies for mergers. The real issue was that Opko used an OVER priced stock to buy a basically OVER priced company. The Thesis was that AT MOST Prolar was only worth 150 million, MAX, and that was considered a GIFT estimate. So Opko paid 480 million 330 million too much using an over priced stock at Opko then 7.15.
The Rolapitant drug was also part of this thesis, I am throwing it in here because according to the THESIS it would NEVER pass phase 3. Well how did that work out? Oh YES, NDA filed. Rayaldee gets lumped in here too as a drug that might pass phase three but never do more than 100m in sales, with that number being a gift too. WE WILL see on that, call, and raise, or whatever poker terminology applies.
The OVER PRICED Prolar deal ? Opko sold co-ownership of ONLY ONE drug in that worthless pipeline, his words not mine, for roughly 570 million dollars. A net profit of 90 million on that worthless over priced Prolar deal. So by this hedge funds logic PFE who is paying 570 million is over paying by 570-150 = 370 million for part ownership of one drug, but wait, they SAID the entire company was worth NO more than 150M, if that.
So I guess I am seeing a theme, that theme would be that sometimes short hedge funds do NOT HAVE a clue when it COMES to VALUING a pipeline. I am not a gambling man, in fact I am a very conservative investor. I do own a couple biotechs but in the 10% of portfolio range. If there were Vegas Odds on Rayaldee hitting
700-800 million year one, I would take that bet. In stage 5 ckd rayaldee will indeed have no sales, but I am convinced it dominates stages 1-4 as the main drug. I think a hedge fund is betting no sales in stage 5 too, missing the mark again.
I gave this a thumb up, lol, I barely or almost never notice those, but felt motivated. Board is garbage, might never improve, but I enjoy sharing opinions. Longs, we win, give it time. SHORTS are road kill, they do not know it yet.